Cartesian Therapeutics (RNAC) Share-based Compensation (2015 - 2026)

Cartesian Therapeutics (RNAC) has reported Share-based Compensation for 12 consecutive years, with $2.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation fell 3.39% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $759000.0 (down 90.09% YoY), while the FY2025 annual figure was $844000.0, down 87.18% from the prior year.
• Share-based Compensation improved to $2.4 million in Q1 2026 per RNAC's latest filing, from -$7.5 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $3.8 million in Q2 2023 and bottomed at -$7.5 million in Q4 2025.
• Historically, Share-based Compensation has averaged $1.3 million across 5 years, with a median of $2.3 million in 2023.
• Annual changes were most pronounced in 2022 — Share-based Compensation surged 173.0% — and 2025, when it slumped 503.91%.
• Cartesian Therapeutics' Share-based Compensation stood at $2.3 million in 2022, then sank by 402.28% to -$6.9 million in 2023, then soared by 127.11% to $1.9 million in 2024, then plunged by 503.91% to -$7.5 million in 2025, then surged by 132.17% to $2.4 million in 2026.
• Business Quant data shows RNAC's Share-based Compensation at $2.4 million in Q1 2026, -$7.5 million in Q4 2025, and $2.6 million in Q3 2025.